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Neuro-oncology, specifically the field of glioma, has witnessed an impressive 
increase in the number of prospective, clinical trials over the last decade. Over 1000 
glioma trials are registered in www.clinicaltrials.gov, and over 400 are actively 
recruiting patients (compare with > 800 recruiting trials in colorectal cancer, or > 1600 
recruiting breast cancer trials). Despite these comparatively numerous trials in a rare 
disease, progress has been slow and a number of randomized trials have failed. 
Have we embarked prematurely on ill-designed clinical trials? 
 
Gliomas and its most aggressive type, glioblastoma, are a heterogeneous diseases 
with variable cells of origin and unique pathogenesis. Although histologically and 
clinically indistinguishable, molecular characteristics of primary (de novo) and 
secondary (arising from a prior lower grade glioma) glioblastoma are distinct; e.g 
epidermal growth factor receptor (EGFR) overexpression and lack of p53 mutations 
are characteristic for primary glioblastoma, and isocitrate dehydrogenase (IDH) 
mutations have recently been identified to be a typical feature of low-grade glioma 
and secondary glioblastoma, suggesting that this is an early event in glioma genesis 
{Yan, 2009 #1155}.  
 
Grossman and colleagues recently pointed out that data from three independent 
phase II trials examining the addition of either the glutamate receptor antagonist 
talampanel, the immune stimulator poly-ICLC, or the integrin antagonist cilengitide all 
appeared to confer a survival benefit compared with standard temozolomide 
radiochemotherapy alone compared to historical controls {Grossman, 2010 #1067}. 
How likely is it that all three new treatment strategies are truly active? The answer is: 
very unlikely. This underscores the importance of randomized controlled trials.  
 
At this year`s ASCO Meeting, the first results of the so far largest trial in glioblastoma 
ever performed were presented {Gilbert, 2011 #1133}. The RTOG0525/ 
EORTC/NCCTG Intergroup Study investigated adjuvant temozolomide dose 
intensification, compared to the standard EORTC-NCIC treatment schedule {Stupp, 
2005 #699}. The trial design was based on (i) the moderate-to-low toxicity of 
temozolomide, (ii) suggestion of an increased antitumor activity with dose-dense 
(alternating week or continuous administration 21/28 days) {Wick, 2004 #670} 
temozolomide regimen in recurrent glioma, (iii) consumption and depletion of the O6-
methylguaninemethyltransferase (MGMT) repair protein in peripheral blood 
mononuclear cells by a protracted temozolomide administration {Tolcher, 2003 #533}.  
The trial was timely and the question pertinent, as almost 1200 patients were enrolled 
within 2 years, and 833 patients were eligible for randomization and adjuvant therapy 
after completing concomitant chemoradiotherapy {Gilbert, 2011 #1133}. There was 
no difference in overall survival (the primary endpoint), and even subgroup analysis 
of the most resistant MGMT-unmethylated tumors, or the patients whose tumors 
harboured a methylated (silenced MGMT gene) and were thus more sensitive to 
alkylating agent chemotherapy, show no hint for improved outcome with 
temozolomide dose intensification. Nevertheless, the design of this trial mandated 
provision of sufficient tumor tissue in order to centrally determine MGMT promoter 
methylation status and allows for exploratory analyses of many other molecular 
abbertions {Aldape, 2011 #1132}. It indeed confirmed the prognostic value of MGMT, 
it demonstrated that time-critical centralized molecular assessment and 
histopathological review is feasible even in a large cooperative group setting, and it 
will be a invaluable resource for further exploratory analyses that shall lead to the 
identification of critical targets, and allow to individualize treatment strategy based on 
molecular tumor characteristics.  
 
We have recently completed accrual to a randomized phase III trial (CENTRIC- 
EORTC # 26071-22072) investigating the adjunction of the integrin inhibitor 
cilengitide in over 500 patients with a methylated MGMT promoter, based on a (too) 
small uncontrolled pilot phase II trial {Stupp, 2010 #1071}. Results are not yet 
available. Similarly, the addition of bevacizumab to standard chemoradiotherapy has 
been investigated in two randomized phase III trials (accrual completed). Long-term 
results of the initial promising reports have been rather disappointing {Lai, 2008 
#944}{Lai, 2011 #1136}. Despite encouraging results of VEGF inhibition by the ligand 
neutralizing antibody bevacizumab {Friedman, 2009 #1036} or receptor tyrosine 
kinase inhibition by cediranib {Batchelor, 2007 #881}{Batchelor, 2010 #1072}, this 
strategy failed to prolong survival in a definitive controlled and randomized trial in 
recurrent disease {Batchelor, 2010 #1131}  
 
Only with controlled trials we will be able to fully appreciate the potential benefit of 
each strategy. Theoretically, it would be attractive to actually combine both integrin 
and VEGF inhibition, however, the current regulatory and pharmaceutical framework 
makes the testing of 2 unregistered agents in combination quite challenging.  
 
At present, we are facing yet another very promising strategy for the treatment of 
newly diagnosed glioblastoma, that is, vaccination with a peptide representing an 
immunogenic epitope of the epidermal growth factor receptor (EGFR) variant III 
mutation, a characteristic type of EGFR mutation found in approximately 25% of all 
glioblastoma patients. Again, uncontrolled phase II look promising {Sampson, 2010 
#1141}, but there is no way around a formal, blinded, comparative study to determine 
whether the promising initial observations result from patient selection or true 
biological activity. The latter would be a highly welcome next step towards more 
treatment options and more individualized cancer therapy for patients with 
glioblastoma.  
 
 
Critical questions arise: what data is needed to justify moving toward pivotal large 
randomized trials. We cannot and do not want to test every “promising” strategy in 
large phase III trials, and a minimum number of patients should be exposed to 
ultimately ineffective novel therapies, while true progress needs to be made available 
as quick as possible. Therefore solid early clinical development is needed, 
randomized phase II trials with one or multiple experimental arms may be a way to go 
forward.  
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